Ad
related to: fda approved peptide therapeutics for cancer
Search results
Results from the WOW.Com Content Network
It was approved in 2014. Nivolumab is approved to treat melanoma, lung cancer, kidney cancer, bladder cancer, head and neck cancer, and Hodgkin's lymphoma. [159] A 2016 clinical trial for non-small cell lung cancer failed to meet its primary endpoint for treatment in the first-line setting, but is FDA-approved in subsequent lines of therapy. [160]
In 2016, the FDA approved atezolizumab for urothelial carcinoma and non-small cell lung cancer. Avelumab (Bavencio) is a fully human IgG1 antibody developed by Merck Serono and Pfizer. Avelumab is FDA approved for the treatment of metastatic merkel-cell carcinoma. It failed phase III clinical trials for gastric cancer. [33]
After clinical trials, in January 2022, the US FDA approved tebentafusp (a BiTE targeting the gp100 peptide) for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. [20]
It was approved in 2014. Nivolumab is approved to treat melanoma, lung cancer, kidney cancer, bladder cancer, head and neck cancer, and Hodgkin's lymphoma. [16] Pembrolizumab (brand name Keytruda) is another PD-1 inhibitor that was approved by the FDA in 2014 and was the second checkpoint inhibitor approved in the United States. [17]
Peptide therapeutics are peptides or polypeptides (oligomers or short polymers of amino acids) which are used to for the treatment of diseases. Naturally occurring peptides may serve as hormones , growth factors , neurotransmitters , ion channel ligands , and anti-infectives ; peptide therapeutics mimic such functions.
(Reuters) -The U.S. Food and Drug Administration on Tuesday approved Johnson & Johnson's chemotherapy-free combination treatment for a type of non-small cell lung cancer, setting up a challenge ...
advanced unresectable or metastatic HER2-positive breast cancer: Pemigatinib: Incyte Corp: metastatic cholangiocarcinoma with FGFR2 fusion Sacituzumab govitecan-hziy: Immunomedics: metastatic triple-negative breast cancer: Capmatinib: Novartis: metastatic non-small cell lung cancer: Selpercatinib: Loxo Oncology: metastatic RET fusion-positive ...
The FDA granted the approval of Lutathera to Advanced Accelerator Applications. [ 6 ] In April 2024, the FDA approved 177 Lu dotatate for the treatment of children aged 12 years and older with somatostatin receptor-positive (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut ...
Ad
related to: fda approved peptide therapeutics for cancer